With a market capitalization (market cap) of $2.01B — a measure of how much the company is worth — AxoGen, Inc. ranks #2,038 among the 2,510 companies tracked, and 250th in Healthcare as of October 3, 2026. Shares trade at $37.39, down 6.34% on the day.
of 2,510 tracked
Market-cap change uses historical capitalization records. Share-price returns are a different series — they can diverge when the share count changes. Those returns are not a CAGR until you pick a start value, an ending value, and years. CAGR calculator. Market cap vs. stock price.
Over the past year, market cap and share price moved by different amounts. Share count can change independently of price. What changes market cap.
Year-end values and the chart both come from historical market-cap records, not from applying today's share count to past prices. Latest historical observation October 2, 2026. Ranking headline cap is the snapshot figure as of October 3, 2026.
| Year | As of | Market cap | Annual change | Year-end close |
|---|---|---|---|---|
| 2026 | Oct 2, 2026 | $1.99B | +18.11% | $37.39 |
| 2025 | Dec 31, 2025 | $1.69B | +126.67% | $32.73 |
| 2024 | Dec 31, 2024 | $744.96M | +153.37% | $16.48 |
| 2023 | Dec 29, 2023 | $294.02M | -30.36% | $6.83 |
| 2022 |
Ranking figure $2.01B as of October 3, 2026.
AxoGen, Inc.'s ranking market cap is the provider-reported capitalization on the same snapshot as the rest of this site, with a share price of $37.39 as of October 2, 2026. Charts and the year-end table use a separate historical market-cap series, last observed at $1.99B on October 2, 2026. See how the ranking works.
Live shares outstanding are not on the quote used for price, so this page does not invent a current share count. Shares outstanding vs. float.
The latest annual report (FY 2025) used a weighted-average 46,050,266 shares. That figure is an average for the year, not the live count in the market-cap formula.
Multiplying the latest price by those FY 2025 weighted-average shares would give about $1.72B. The ranking uses the provider's reported market cap instead, which reflects a current share count rather than that annual average.
Book equity: assets minus liabilities on the latest annual report.
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
Not in this snapshot
FY 2025 net worth
Largest U.S.-listed names in the same FMP sector — not a hand-picked competitor set.
| Rank | Company | Market cap | 1D |
|---|---|---|---|
| #14 | Eli Lilly and Company LLY | $1.08T | -0.61% |
| #21 | Johnson & Johnson JNJ | $617.01B | -1.02% |
| #24 |
AxoGen, Inc., along with its subsidiaries, specializes in creating and distributing medical devices for the surgical repair of injured or severed peripheral nerves. Their comprehensive product portfolio offers several innovative solutions. The Avance Nerve Graft is a ready-to-use, biologically active human nerve allograft designed to bridge gaps in severed nerves.
Summary from the company profile (Financial Modeling Prep). Principal financial figures above are for FY 2025.
Visit websiteAs of October 3, 2026, AxoGen, Inc. (AXGN) is worth $2.01B — that is its market capitalization, the total value of its outstanding shares on MarketCapLens.
A company’s net worth is its shareholders’ equity: assets minus liabilities on the balance sheet. That is book equity, not market cap. For FY 2025, AxoGen, Inc.’s book equity is about $128.85M. Market cap is the market value of the outstanding shares. As of October 3, 2026, its market cap is $2.01B. Book equity is an accounting remainder; market cap is a trading value. Neither is a person’s net worth.
AxoGen, Inc. ranks #2,038 among the 2,510 companies tracked on MarketCapLens. In Healthcare it ranks #250 of 350.
Fundamentals are annual. Figures labeled with their fiscal year. Live ratios use the current price against those annual earnings.
| Dec 30, 2022 |
| $422.21M |
| +7.79% |
| $9.98 |
| 2021 | Dec 31, 2021 | $391.7M | — | $9.37 |
|---|
Last observation of each calendar year from historical market-cap records. The current year is through the latest date, not a completed year-end. Share-price close is the matching session for context — we do not rebuild cap from today's share count.
Not in this snapshot
FY 2025
| $464.35B |
| +1.11% |
| #36 | Merck & Co., Inc. MRK | $356.4B | +0.34% |
| #38 | UnitedHealth Group Incorporated UNH | $337.74B | +1.83% |
| #52 | Novartis AG NVS | $268B | -0.04% |
Companies immediately above and below in the overall ranking. They may be in a different sector.
| Rank | Company | Market cap | 1D |
|---|---|---|---|
| #2035 | LCI Industries LCII | $2.01B | +0.85% |
| #2036 | SolarEdge Technologies, Inc. SEDG | $2.01B | +7.19% |
| #2037 | Allient Inc. ALNT | $2.01B | +2.03% |
| #2039 | Under Armour, Inc. UAA | $2.01B | +1.51% |
| #2040 | GigaCloud Technology Inc. GCT | $2.01B | +1.05% |
| #2041 | Perdoceo Education Corporation PRDO | $2B | +0.28% |
AxoGen, Inc.’s ranking market cap of $2.01B comes from the same snapshot as the rest of this site, as of October 3, 2026. It is not share price multiplied by the FY 2025 weighted-average share count of 46,050,266. The historical market-cap series last observed $1.99B on October 2, 2026.
Over the past year, AxoGen, Inc.’s market cap is up 137.68%, using historical market-cap records rather than today’s share count applied to past prices.
AxoGen, Inc. (AXGN) shares trade at $37.39, down 6.34% on the day, as of October 3, 2026.
Live P/E is share price divided by annual earnings per share. It is blank when earnings are missing, zero, or negative — not a 0× multiple.